12:00 AM
 | 
Aug 28, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enoximone: Phase II data; Phase III; Intravenous formulation marketed in Europe

Myogen collaborators published in the Journal of the American College of Cardiology results of a placebo-controlled 105-patient U.S. trial showing that low doses of oral enoximone improved exercise capacity in CHF patients. Higher doses are associated with increased mortality, the researchers noted. However, over 12 weeks of...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >